See how Novartis is responding to Coronavirus (COVID-19)
This site is intended for UK healthcare professionals only. If you are a member of the public, please click here
Professor Caroline Robert (Head of the Dermatology Unit at Gustave Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University) presents the latest 5-year data (pooled analysis) on the use of Tafinlar + Mekinist for the management of BRAF V600 metastatic melanoma.
Filmed June 2019.
The separate data from the COMBI-v and COMBI-d trials, on which this is based, can be viewed here.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]
